Drug Combination Details
| General Information of the Combination (ID: C78359) | |||||
|---|---|---|---|---|---|
| Name | Cladribine NP Info | + | S3I-201 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | ||
| RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
| MM1.S | CVCL_8792 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
Cladribine exhibited inhibitory effects on MM cells in vitro. MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011 Jun 16;11:255. | |||
